Philip S Rudland

Affiliations: 
Biochemistry University of Liverpool, LIVERPOOL, UK. 
Google:
"Philip Rudland"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Ismail TM, Crick RG, Du M, et al. (2023) Targeted Destruction of S100A4 Inhibits Metastasis of Triple Negative Breast Cancer Cells. Biomolecules. 13
Du M, Wang G, Barsukov IL, et al. (2020) Direct interaction of metastasis-inducing S100P protein with tubulin causes enhanced cell migration without changes in cell adhesion. The Biochemical Journal
Al-Jameel W, Gou X, Jin X, et al. (2019) Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARγ. Genes & Cancer. 10: 80-96
Naeem AA, Abdulsamad SA, Rudland PS, et al. (2019) Fatty acid-binding protein 5 (FABP5)-related signal transduction pathway in castration-resistant prostate cancer cells: a potential therapeutic target Precision Clinical Medicine. 2: 192-196
Dakir EH, Pickard A, Srivastava K, et al. (2018) The anti-psychotic drug pimozide is a novel chemotherapeutic for breast cancer. Oncotarget. 9: 34889-34910
Kamal A, Valentijn A, Barraclough R, et al. (2018) High AGR2 protein is a feature of low grade endometrial cancer cells. Oncotarget. 9: 31459-31472
Tabrizi MEA, Lancaster TL, Ismail TM, et al. (2018) S100P enhances the motility and invasion of human trophoblast cell lines. Scientific Reports. 8: 11488
Zakaria R, Platt-Higgins A, Rathi N, et al. (2017) T cell densities in brain metastases are associated with patient survival times and diffusion tensor MRI changes. Cancer Research
Clarke C, Gross SR, Ismail TM, et al. (2017) Activation of tissue plasminogen activator by metastasis-inducing S100P protein. The Biochemical Journal
Chan KK, Matchett KB, Coulter JA, et al. (2017) Erythropoietin drives breast cancer progression by activation of its receptor EPOR. Oncotarget
See more...